Moreover, the dominant presence of studies reporting on the clinical validity of LBs in the detection of EGFR mutations found in this review is in line with the view of the International Association for the Study of Lung Cancer, and it is to be expected that the first role of LBs in the management of NSCLC will involve detection of EGFR mutations. Here, EGFR is linked to lung cancer.